ADMP - Adamis Pharmaceuticals: It's Now Or Never

• Adamis Pharmaceuticals has two FDA-approved products and a potential blockbuster drug in TEMPOL. However, the company has a long history of blunders that have devastated the share price.
• I believe the company has a chance to make 2022 a turnaround year, but it is going to require making deals and not excuses to get investors reinvigorated about ADMP.
• I discuss some of the leading downside risks that investors should be aware of.
• Finally, I reveal my plan for trading ADMP through the rest of 2021 and throughout 2022.

For further details see: